USP18 and leukemia: Interestingly, this resistance to oncogenic transformation is largely due to the hypersensitivity of USP18-deficient cells to type I IFN signaling, raising the possibility that USP18 is pivotal for the control of the latency and severity of leukemia development and that abrogation of USP18-mediated downregulation of IFN signaling could potentiate the effects of type I IFNs against cancer development.